高级检索

晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)

上一篇

下一篇

文章导航 > 临床泌尿外科杂志 > 2022 > 37(5): 329-337
中国抗癌协会泌尿男生殖系肿瘤专业委员会肾癌学组. 晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)[J]. 临床泌尿外科杂志, 2022, 37(5): 329-337. doi: 10.13201/j.issn.1001-1420.2022.05.001
引用本文: 中国抗癌协会泌尿男生殖系肿瘤专业委员会肾癌学组. 晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)[J]. 临床泌尿外科杂志, 2022, 37(5): 329-337. doi: 10.13201/j.issn.1001-1420.2022.05.001
shu
Chinese experts' consensus on the optimization of first-line target therapy for advanced clear cell renal cell carcinoma(2022)[J]. J Clin Urol, 2022, 37(5): 329-337. doi: 10.13201/j.issn.1001-1420.2022.05.001
Citation: Chinese experts' consensus on the optimization of first-line target therapy for advanced clear cell renal cell carcinoma(2022)[J]. J Clin Urol, 2022, 37(5): 329-337. doi: 10.13201/j.issn.1001-1420.2022.05.001
shu

晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)

详细信息

    肾癌学组组长: 李长岭
    肾癌学组副组长: 齐隽 陈立军 张爱莉 李响
    执笔人: 韩苏军, 中国医学科学院肿瘤医院
    李响, 四川大学华西医院
    通信作者: 李响, E-mail: xiangli.87@163.com

  • 中图分类号: R737.11

Chinese experts' consensus on the optimization of first-line target therapy for advanced clear cell renal cell carcinoma(2022)

    摘要
    • HTML全文
  • 加载中

  • 图 1  免疫联合治疗RCT临床研究结果及亚组分析数据汇总

    下载: 全尺寸图片 幻灯片

    表 1  舒尼替尼临床研究结果汇总

    真实世界研究 Ⅲ期扩大研究 ADONIS IMDC 中国Ⅳ期
    研究设计 / 前瞻性+回顾性 回顾性 前瞻性
    患者/例 4543(一线占比22.2%) 555 1769(一线占比96.3%) 105
    ORR/% 16 40 32.4 31.1
    mPFS/月 9.7 10.4 8.1 14.2
    下载: 导出CSV

    表 2  培唑帕尼临床研究结果汇总

    真实世界研究 PRINCIPAL SPAZO 意大利 匈牙利 中国1 中国2
    研究设计 前瞻性 回顾性 回顾性 回顾性 回顾性 回顾性
    患者/例 657 278 474 81 31 32
    ORR/% 30.3 30.3 35.9 43 34.5 37.5
    mPFS/月 10.3 11.1 15.8 11.8 10.1 18.3
    下载: 导出CSV
    • 参考文献(51)
  • [1]

    Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3: 17009. doi: 10.1038/nrdp.2017.9

    [2]

    MB Amin, SB Edge, FL Greene, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2017.

    [3]

    Hara T, Fujimoto H, Kondo T, et al. Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association[J]. Jpn J Clin Oncol, 2017, 47(12): 1162-1169. doi: 10.1093/jjco/hyx129

    [4]

    Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma[J]. J Clin Oncol, 2002, 20(1): 289-296. doi: 10.1200/JCO.2002.20.1.289

    [5]

    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study[J]. J Clin Oncol, 2009, 27(34): 5794-5799. doi: 10.1200/JCO.2008.21.4809

    [6]

    Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma[J]. Semin Nephrol, 2020, 40(1): 76-85. doi: 10.1016/j.semnephrol.2019.12.009

    [7]

    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase Ⅲ trial[J]. Lancet, 2008, 372(9637): 449-456. doi: 10.1016/S0140-6736(08)61039-9

    [8]

    Singla N. Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma(IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393: 2404-15: Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma[J]. Eur Urol, 2020, 77(6): e168-e169. doi: 10.1016/j.eururo.2019.09.015

    [9]

    Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. doi: 10.1056/NEJMoa2035716

    [10]

    Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma(KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573. doi: 10.1016/S1470-2045(20)30436-8

    [11]

    Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial[J]. Nat Med, 2020, 26(11): 1733-1741. doi: 10.1038/s41591-020-1044-8

    [12]

    Cella D, Motzer RJ, Suarez C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 292-303. doi: 10.1016/S1470-2045(21)00693-8

    [13]

    Motzer RJ, Tannir NM, Mcdermott D, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. doi: 10.1056/NEJMoa1712126

    [14]

    Pruis SL, Aziz M, Pearce F, et al. Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore[J]. Int J Technol Assess Health Care, 2019, 35(2): 126-133. doi: 10.1017/S0266462319000059

    [15]

    Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2013, 369(8): 722-731. doi: 10.1056/NEJMoa1303989

    [16]

    Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2010, 28(6): 1061-1068. doi: 10.1200/JCO.2009.23.9764

    [17]

    Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. doi: 10.1056/NEJMoa2035716

    [18]

    Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial-ScienceDirect[J]. Eur Urol, 2021, 79(5): 659-662. doi: 10.1016/j.eururo.2020.06.021

    [19]

    Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma[J]. Clin Cancer Res, 2021, 27(1): 78-86. doi: 10.1158/1078-0432.CCR-20-2063

    [20]

    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27(22): 3584-3590. doi: 10.1200/JCO.2008.20.1293

    [21]

    Gore ME, Szczylik C, Porta C, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma[J]. Br J Cancer, 2015, 113(1): 12-19. doi: 10.1038/bjc.2015.196

    [22]

    Lee JL, Kim MK, Park I, et al. RandomizEd phase Ⅱ trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial[J]. Ann Oncol, 2015, 26(11): 2300-2305. doi: 10.1093/annonc/mdv357

    [23]

    Laguna MP. Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. J Urol, 2017, 197(3 Pt 1): 603.

    [24]

    Schmidinger M, Porta C, Oudard S, et al. Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score[J]. Clin Genitourin Cancer, 2020, 18(5): e588-e597. doi: 10.1016/j.clgc.2020.02.013

    [25]

    Savard MF, Wells JC, Graham J, et al. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma(mRCC)by the International mRCC Database Consortium Risk Group[J]. Oncologist, 2020, 25(5): 422-430. doi: 10.1634/theoncologist.2019-0605

    [26]

    O'Brien ME, Gaafar R, Hasan B, et al. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase Ⅲ study of the lung cancer group, EORTC 08092(EudraCT: 2010-018566-23, NCT01208064)[J]. Eur J Cancer, 2015, 51(12): 1511-1528. doi: 10.1016/j.ejca.2015.04.026

    [27]

    Schmidinger M, Bamias A, Procopio G, et al. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma(PRINCIPAL Study)[J]. Oncologist, 2019, 24(4): 491-497. doi: 10.1634/theoncologist.2018-0787

    [28]

    Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, et al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium(IMDC)prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group(SOGUG)SPAZO study[J]. Ann Oncol, 2016, 27(4): 706-711. doi: 10.1093/annonc/mdv601

    [29]

    Mosca A, De Giorgi U, Procopio G, et al. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study[J]. Jpn J Clin Oncol, 2021, 51(3): 484-491. doi: 10.1093/jjco/hyaa193

    [30]

    Küronya Z, Szönyi MD, Nagyiványi K, et al. Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer[J]. Pathol Oncol Res, 2020, 26(4): 2475-2481. doi: 10.1007/s12253-020-00853-9

    [31]

    Wang B, Song JW, Chen HQ. First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Cente[J]. Front Pharmacol, 2020, 11: 517672. doi: 10.3389/fphar.2020.517672

    [32]

    Chen J, Ye W, Jiang W, et al. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study[J]. Transl Androl Urol, 2021, 10(3): 1321-1331. doi: 10.21037/tau-21-111

    [33]

    Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib[J]. N Engl J Med, 2014, 370(18): 1769-1770. doi: 10.1056/NEJMc1400731

    [34]

    Sheng X, Jin J, He Z, et al. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies[J]. BMC Cancer, 2020, 20(1): 219. doi: 10.1186/s12885-020-6708-8

    [35]

    Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study[J]. J Clin Oncol, 2014, 32(14): 1412-1418. doi: 10.1200/JCO.2013.50.8267

    [36]

    Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial[J]. J Clin Oncol, 2017, 35(6): 591-597. doi: 10.1200/JCO.2016.70.7398

    [37]

    Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk(Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update[J]. Eur J Cancer, 2018, 94: 115-125. doi: 10.1016/j.ejca.2018.02.012

    [38]

    Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma(KEYNOTE-426): extended follow-up fr om a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573. doi: 10.1016/S1470-2045(20)30436-8

    [39]

    Rini B, Plimack E, Stus V, et al. Pembrolizumab(pembro)plus axitinib(axi)versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma(ccRCC): Results from 42-month follow-up of KEYNOTE-426[J/OL]. J Clin Oncol, 2021, 39(suppl 15, abstract 4500).

    [40]

    Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma[J]. Ann Oncol, 2020, 31(8): 1030-1039. doi: 10.1016/j.annonc.2020.04.010

    [41]

    Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2021, 384(9): 829-841. doi: 10.1056/NEJMoa2026982

    [42]

    Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial[J]. J Immunother Cancer, 2020, 8(2): e000891. doi: 10.1136/jitc-2020-000891

    [43]

    Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. doi: 10.6004/jnccn.2020.0012

    [44]

    Motzer RJ, Banchereau R, Hamidi H, et al. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade[J]. Cancer Cell, 2020, 38(6): 803-817.e4. doi: 10.1016/j.ccell.2020.10.011

    [45]

    Epaillard N, Simonaggio A, Elaidi R, et al. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor(TKI)in naïve metastatic kidney cancer[J]. Bull Cancer, 2020, 107(5S): eS22-eS27.

    [46]

    Chen J, Ye W, Jiang W, et al. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study[J]. Transl Androl Urol, 2021, 10(3): 1321-1331. doi: 10.21037/tau-21-111

    [47]

    Voss MH, Reising A, Cheng Y, et al. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study[J]. Lancet Oncol, 2018, 19(12): 1688-1698. doi: 10.1016/S1470-2045(18)30648-X

    [48]

    Liu XD, Kong W, Peterson CB, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma[J]. Nat Commun, 2020, 11(1): 2135. doi: 10.1038/s41467-020-15959-6

    [49]

    Apolo AB, Powles T, Burotto M, et al. Nivolumab plus cabozantinib(N+C)versus sunitinib(S)for advanced renal cell carcinoma(aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial[J]. J Clini Oncol, 2021, 39(15_suppl): 4553-4553. doi: 10.1200/JCO.2021.39.15_suppl.4553

    [50]

    Dudani S, de Velasco G, Wells JC, et al. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival[J]. JAMA Netw Open, 2021, 4(1): e2021869. doi: 10.1001/jamanetworkopen.2020.21869

    [51]

    张浩然, 张兴明, 朱旭东, 等. 不同部位转移灶对肾癌患者预后的影响及其对IMDC评分的改良价值[J]. 中华泌尿外科杂志, 2020, 41(6): 439-445. doi: 10.3760/cma.j.cn112330-20200501-00345

    • 相关文章
  • 施引文献
  • 资源附件(0)
  • 加载中

图(1)

表(2)

计量
  • 文章访问数:  3749
  • PDF下载数:  6174
  • 施引文献:  0
出版历程
收稿日期:  2022-02-20
刊出日期:  2022-05-06

目录

    返回

    用微信扫描二维码

    分享至好友和朋友圈

    地址：

    邮政编码：

    电话：

    E-mail： lcmnwkzz@whuh.com

    {{newsColumn.name}}

    {{news.title}}

    版权所有 © 武汉协和医院杂志社 鄂ICP备 05004666-1 技术支持： 北京仁和汇智信息技术有限公司